| 产品描述: | SR59230A is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively |
| 靶点: |
IC50: 40 nM (β3 receptor), 408 nM ((β1 receptor), 648 nM (β2 receptor);AdrenergicReceptor |
| 体内研究: |
MDMA (20 mg/kg) produces a slowly developing hyperthermia, reaching a maximum increase of 1.8°C at 130 min post injection. SR59230A (0.5 mg/kg) produces a small but significant attenuation of the slowly developing hyperthermia to MDMA. SR59230A (5 mg/kg) reveals a significant and marked early hypothermic reaction to MDMA. Animal Model: Male C-57BL6J wild-type mice (22-35 g) Dosage: 0.5 or 5 mg/kg Administration: Injected s.c.; administered 30 min prior to the injection s.c. of MDMA (20 mg/kg). Result: Modulated the actions of MDMA on temperature involve α1-adrenoceptor antagonism. |
| 参考文献: |
1. Nisoli E, et al. Functional studies of the first selective beta 3-adrenergic receptor antagonist SR 59230A in rat brown adipocytes.Mol Pharmacol. 1996 Jan;49(1):7-14. 2. Kanzler SA, et al. Involvement of β3-adrenergic receptors in the control of food intake in rats.Braz J Med Biol Res. 2011 Nov;44(11):1141-7. 3. Bruno G, et al. β3-adrenoreceptor blockade reduces tumor growth and increases neuronal differentiation in neuroblastoma via SK2/S1P2 modulation.Oncogene. 2020 Jan;39(2):368-384. 4. Bexis S, et al. Role of alpha 1- and beta 3-adrenoceptors in the modulation by SR59230A of the effects of MDMA on body temperature in the mouse. Br J Pharmacol. 2009 Sep;158(1):259-66. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.407 ml |
12.034 ml |
24.069 ml |
| 5 mM |
0.481 ml |
2.407 ml |
4.814 ml |
| 10 mM |
0.241 ml |
1.203 ml |
2.407 ml |
| 50 mM |
0.048 ml |
0.241 ml |
0.481 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |